Year in Review: Updates in Treating Myelofibrosis - Episode 7

Future Directions in Combination Therapies for Myelofibrosis

,

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, reflect on the future of combination therapies in treating myelofibrosis, emphasizing the need to align study endpoints with treatment goals and highlighting the potential of various combinations based on promising preclinical and early phase study results.

EP. 1: How JAK Inhibitors Have Shaped the Landscape of MF
EP. 2: Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2
EP. 3: Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1
EP. 4: Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib
EP. 5: Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034
EP. 6: Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001
Now Viewing
EP. 7: Future Directions in Combination Therapies for Myelofibrosis
EP. 8: Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF
EP. 9: The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib
EP. 10: Selection and Sequencing of JAK Inhibitors for Patients With MF
EP. 11: Individualizing Therapy Goals for Patients With Myelofibrosis
EP. 12: Emerging Treatments for Myelofibrosis